Description

As a master regulator of Th2 immunity, IL-4 activates the JAK1/3-STAT6 signaling cascade via the IL-4Rα/γc receptor complex, directing naive CD4+ T-cell differentiation into Th2 effectors secreting IL-5/IL-13 while mediating B-cell class switching to IgE/IgG1 and FcεRI upregulation.

The recombinant human IL-4-His fusion protein is a high-purity functional cytokine produced in HEK-293 expression systems, featuring a C-terminal hexahistidine tag to facilitate affinity purification and structural integrity.

In cell therapy applications, this protein serves as an essential inducer for monocyte-derived immature dendritic cell (imDC) generation through GM-CSF synergy, effectively suppressing CD14 expression and enhancing antigen-capturing capacity to standardize tumor vaccine production.

It also modulates CAR-T cell manufacturing by balancing Th1/Th2 polarization for optimized solid tumor responses and prolongs mast cell survival in vitro to enhance stability of allergen-specific immunotherapies.

The HEK-293-derived expression ensures authentic glycosylation patterns, while the His-tag maintains native conformation and enables high-resolution chromatographic purification.

Specifications

Specification	Acceptance Criteria	Results
Appearance	Freeze-dried preparation, the form should be white loose body	Compliance
Identity	The electrophoretic bands should be consistent with the molecular weight of the product	Compliance
Visible Particle	Should be no visible particle	Compliance
Moisture	≤4.0%	1.0%
pH	6.5~7.5	7.2
Purity	>90.0%	Compliance
Endotoxin	<0.1EU/μg	<0.1EU/μg
Mycoplasma	Should be negative	Negative
Sterility	No growth	No growth
Biological Activity	Cell proliferation assay was performed with TF-1 cells, and the activity ≥ 1×10⁶ IU/mg	7.9×10⁶ IU/mg

Features

✔ High Biological Potency (TF-1 Validated)
Demonstrates strong proliferative activity in TF-1 cell assays (7.9 × 10⁶ IU/mg), ensuring reliable Th2-skewing and DC induction performance.
✔ HEK293 Expression with Authentic Glycosylation
Mammalian expression preserves native folding and glycosylation, supporting consistent IL-4Rα/γc signaling activation.
✔ Low Endotoxin, Cell-Therapy Compatible
Endotoxin level < 0.1 EU/µg and mycoplasma-negative, suitable for immune cell culture and CGT research workflows.
✔ Batch-to-Batch Consistency
Manufactured under controlled QC standards with verified purity (>90% SDS-PAGE), minimizing experimental variability.

Applications

Monocyte-Derived Dendritic Cell (imDC) Generation

Used synergistically with GM-CSF to suppress CD14 expression and drive standardized immature DC differentiation.

T-Cell Polarization Studies

Directs naïve CD4⁺ T cells toward Th2 lineage via STAT6 activation, supporting immune-profiling research.

CAR-T / CGT Process Development

Modulates Th1/Th2 balance during T-cell manufacturing to optimize functional phenotype for solid tumor research.

Mast Cell & Allergy Research Models

Prolongs mast cell survival in vitro, enabling stable allergen-response and IgE-related studies.

Stability & Storage

Lyophilized powder: Store at −20 °C in the original sealed container.
Reconstitution: Reconstitute with sterile Water for Injection, 0.9% NaCl, or PBS (pH 7.4) prior to use.
Handling: Aliquot after reconstitution and avoid repeated freeze–thaw cycles.

Cautions

• Research Use Only: This product is not intended for diagnostic or therapeutic use.

• Handling: Prepare solutions using sterile technique. Avoid microbial contamination to maintain activity.

• Storage: Follow recommended storage conditions. Repeated freeze–thaw cycles may reduce performance.

Documents

📄 TL-301 Data Sheet 📄 TL-301 SDS 📄 TL-301 COA

Recombinant Human IL-4 Protein